Harlan S Robins

CSO Harlan S Robins sells 106,160 shares for $1,847,941.60 under pre-arranged 10b5-1 plan at ADPT

Harlan S Robins, Chief Scientific Officer at Adaptive Biotechnologies, executed 2 separate sales totaling 106,160 shares for $1,847,941.60 on 2026-06-15 and 2026-06-16, reducing his holdings by 7.0% to 1,405,898 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-13, meaning it was scheduled rather than discretionary. At the time of sale, the blended average price of $17.41 was within the 52-week range of $9.90–$20.76, though currently the stock trades at $16.78, -19.2% from the 52-week high. Across his cross-ticker track record, Robins' prior 2 sells showed an average 90-day return of +31.8%, and at this same ticker (ADPT), his 2 prior trades on 2026-03-11 also showed +31.8% 90-day returns, though the scheduled nature of this transaction means timing characteristics do not apply to the filing itself. The underlying company reported $70.9M in quarterly revenue with annual growth of +54.8%, but remained unprofitable with -$20.0M net income, indicating this is a growth-stage biotech still advancing toward profitability.

CSO Harlan S. Robins sold 470,266 shares for $6,193,403.22 at $13.17; holds 1,522,058 post-sale; stock -35.6% from 52-week high.

Harlan S. Robins, Chief Scientific Officer, executed 2 separate sales totaling 470,266 shares for $6,193,403.22 at $13.17 per share on 2026-03-11, reducing his holdings by 23.6%. The sale occurs as ADPT stock trades -35.6% below its 52-week high and -15.7% over the past 30 days, with the company currently unprofitable on a full-year basis despite strong revenue growth of 54.8% and an elevated P/E of 101.31. The CSO's significant equity reduction during a period of depressed valuation and recent downward momentum warrants investor attention to whether this reflects confidence constraints or broader company concerns.